SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Leboulleux Sophie)
 

Sökning: WFRF:(Leboulleux Sophie) > Gelderblom Hans > Combination chemoth...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004764naa a2200721 4500
001oai:DiVA.org:uu-175725
003SwePub
008120612s2012 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:124695113
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1757252 URI
0247 a https://doi.org/10.1056/NEJMoa12009662 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1246951132 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Fassnacht, Martin4 aut
2451 0a Combination chemotherapy in advanced adrenocortical carcinoma
264 1c 2012
338 a print2 rdacarrier
520 a BACKGROUND:Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment.METHODS:We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival.RESULTS:For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate than those in the streptozocin-mitotane group (23.2% vs. 9.2%, P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no significant between-group difference in overall survival (14.8 months and 12.0 months, respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P=0.07). Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitotane group. Patients who did not receive the alternative second-line therapy had better overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious adverse events did not differ significantly between treatments.CONCLUSIONS:Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival.
7001 a Terzolo, Massimo4 aut
7001 a Allolio, Bruno4 aut
7001 a Baudin, Eric4 aut
7001 a Haak, Harm4 aut
7001 a Berruti, Alfredo4 aut
7001 a Welin, Staffanu Uppsala universitet,Institutionen för medicinska vetenskaper,Onkologisk endokrinologi4 aut0 (Swepub:uu)stafweli
7001 a Schade-Brittinger, Carmen4 aut
7001 a Lacroix, André4 aut
7001 a Jarzab, Barbara4 aut
7001 a Sorbye, Halfdan4 aut
7001 a Torpy, David J4 aut
7001 a Stepan, Vinzenz4 aut
7001 a Schteingart, David E4 aut
7001 a Arlt, Wiebke4 aut
7001 a Kroiss, Matthias4 aut
7001 a Leboulleux, Sophie4 aut
7001 a Sperone, Paola4 aut
7001 a Sundin, Andersu Karolinska Institutet,Uppsala universitet,Enheten för radiologi4 aut0 (Swepub:uu)anderssu
7001 a Hermsen, Ilse4 aut
7001 a Hahner, Stefanie4 aut
7001 a Willenberg, Holger S4 aut
7001 a Tabarin, Antoine4 aut
7001 a Quinkler, Marcus4 aut
7001 a de la Fouchardière, Christelle4 aut
7001 a Schlumberger, Martin4 aut
7001 a Mantero, Franco4 aut
7001 a Weismann, Dirk4 aut
7001 a Beuschlein, Felix4 aut
7001 a Gelderblom, Hans4 aut
7001 a Wilmink, Hanneke4 aut
7001 a Sender, Monica4 aut
7001 a Edgerly, Maureen4 aut
7001 a Kenn, Werner4 aut
7001 a Fojo, Tito4 aut
7001 a Müller, Hans-Helge4 aut
7001 a Skogseid, Brittu Uppsala universitet,Institutionen för medicinska vetenskaper,Endokrin tumörbiologi4 aut0 (Swepub:uu)brittsko
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t New England Journal of Medicineg 366:23, s. 2189-2197q 366:23<2189-2197x 0028-4793x 1533-4406
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-175725
8564 8u https://doi.org/10.1056/NEJMoa1200966
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:124695113

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy